tert-Butyl 3-bromo-6,6-dimethyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate

Catalog No.: 
ACRVLU459
CAS No.: 
2089334-44-9
Molecular Formula: 
C13H20BrN3O2
Molecular Weight: 
330.23
tert-Butyl 3-bromo-6,6-dimethyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
100mg97%$272.00InquiryInquiry
250mg97%$515.00InquiryInquiry
1g97%$1494.00InquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 3-bromo-6,6-dimethyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
IUPAC Nametert-butyl 3-bromo-6,6-dimethyl-5,6-dihydroimidazo[1,5-a]pyrazine-7(8H)-carboxylate
MDL No.MFCD30528463
Molecular FormulaC13H20BrN3O2
Molecular Weight330.23
SMILESO=C(N1CC2=CN=C(Br)N2CC1(C)C)OC(C)(C)C
InChI KeyJHDIZIKTYRMJEE-UHFFFAOYSA-N
SynonymImidazo[1,5-a]pyrazine-7(8H)-carboxylic acid, 3-bromo-5,6-dihydro-6,6-dimethyl-, 1,1-dimethylethyl ester
CAS No.2089334-44-9

Safety Data

Pictogram
Harmful or irritant
Signal Word
Warning
Hazard Statement(s)
H315-H319-H335
Precautionary Statement(s)
P261-P305+P351+P338

Synthetic Route by SureRoute

1. ACRVLU459 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACRVLU459 route product structure diagram
    ACRVLU4592089334-44-9
Inquiry

2. ACRVLU459 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRVLU459 route product structure diagram
    ACRVLU4592089334-44-9
Inquiry

3. ACRVLU459 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACRVLU459 route product structure diagram
    ACRVLU4592089334-44-9
Inquiry

Comments (0)